Does Blue Cross Blue Shield of Alabama Cover Jardiance?

What Is Jardiance and Why Does Coverage Matter?

Jardiance (empagliflozin) is an SGLT2 inhibitor approved by the FDA for three separate indications: glycemic control in type 2 diabetes mellitus, reduction of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, and reduction of cardiovascular death or hospitalization in adults with heart failure. The FDA expanded coverage to heart failure with preserved ejection fraction (HFpEF) in 2022 and to chronic kidney disease (CKD) in 2023. Each approval is backed by a distinct outcomes trial, and that clinical breadth directly affects how insurers classify the drug.

Because empagliflozin is still under patent and carries a retail price above $573 per 30-day supply, which tier your BCBS Alabama plan places it on can mean the difference between a $10 copay and a $500 monthly bill. The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 14% versus placebo (HR 0.86; 95% CI 0.74, 0.99; P<0.001 for non-inferiority and P=0.04 for superiority) [1]. That outcome data, combined with subsequent heart failure and CKD trials, is why guidelines now recommend empagliflozin for patients with diabetes and high cardiovascular risk even when glucose control is already adequate.

Understanding your plan's formulary, the prior authorization criteria, and the appeals process is not optional paperwork. It is a direct determinant of whether a medication with proven mortality benefit reaches you.

How Blue Cross Blue Shield of Alabama Structures Its Formularies

BCBS Alabama uses a tiered formulary system across its commercial individual, small-group, large-group, and Medicare Advantage (Blue Advantage) product lines. Tiers generally run from Tier 1 (generic preferred) through Tier 5 or Tier 6 (specialty). Jardiance most commonly lands on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) depending on the specific plan year and product.

Tier placement matters financially. A Tier 3 designation under a typical BCBS Alabama PPO might carry a $60, $100 copay after the deductible is met. A Tier 4 designation could mean 40 to 50% coinsurance, which on a $580 drug translates to $232, $290 per fill. Plans with a high deductible (HDHP) require you to pay the full negotiated price until your deductible is satisfied, often meaning $300, $450 per fill for several months of the plan year.

The American Diabetes Association's 2024 Standards of Care in Diabetes recommend SGLT2 inhibitors with proven cardiovascular benefit for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or CKD regardless of baseline HbA1c [2]. Insurers are therefore under clinical and regulatory pressure to include these agents on formulary, but they retain discretion over tier placement and utilization management requirements.

To confirm your specific tier, log in to the BCBS Alabama member portal (bcbsal.org), manage to "Drug Coverage and Cost," and enter "empagliflozin" or "Jardiance" along with your current plan year. The real-time formulary tool will display your tier, any applicable prior authorization (PA) flags, step-therapy requirements, and estimated copay both before and after your deductible.

Prior Authorization Requirements for Jardiance Under BCBS Alabama

Prior authorization is the most common barrier patients encounter. Most BCBS Alabama commercial plans require PA for Jardiance, and approval typically depends on satisfying a short clinical checklist.

Standard PA criteria across BCBS Alabama plans generally include:

• Confirmed diagnosis of type 2 diabetes, heart failure, or CKD (depending on the indication being authorized)
• Documentation that the prescribing provider is treating the patient for the approved indication
• Evidence that metformin has been tried and either failed, was not tolerated, or is contraindicated (for the diabetes indication)
• Recent HbA1c result (commonly within the past 12 months) for diabetes PA requests
• eGFR documentation for CKD or heart failure indications

The PA process typically takes 1, 3 business days for standard review or 24 to 72 hours for urgent requests. FDA guidance on step therapy and prior authorization in Medicare Advantage plans states that plans must respond to standard requests within 72 hours and expedited requests within 24 hours [3]. While that federal rule specifically governs Medicare Advantage, BCBS Alabama's commercial plans follow similar internal timelines.

Your prescribing physician's office handles the PA paperwork, but you can speed the process by ensuring your chart includes a current HbA1c, an eGFR if relevant, and a documented trial of or contraindication to metformin before the PA is submitted.

Step Therapy: What It Is and How It Affects Your Jardiance Access

Step therapy, sometimes called "fail-first" policy, requires you to try and fail a less expensive medication before the insurer will authorize a costlier one. For Jardiance prescribed for type 2 diabetes, BCBS Alabama plans commonly require a documented trial of metformin, a sulfonylurea, or a DPP-4 inhibitor first.

This requirement is clinically contested. A 2022 position statement from the American Association of Clinical Endocrinology (AACE) stated that step therapy protocols that delay access to SGLT2 inhibitors and GLP-1 receptor agonists in patients with cardiovascular disease or CKD are "potentially harmful" because they postpone proven organ-protective therapies [4]. Physicians can request a step-therapy exception by documenting that step therapy would delay a medically necessary, guideline-supported treatment, or that the patient already has contraindications to the required first-step agents.

Alabama state law (Alabama Code Section 27-52-3 as amended) sets a maximum 30-day timeline for insurers to respond to a step-therapy exception request. If your plan denies the exception, the denial triggers your right to a formal appeal.

Understanding the Three Medicare Advantage Scenarios

BCBS Alabama offers Blue Advantage HMO and PPO plans for Medicare beneficiaries. Jardiance's coverage under these plans follows Medicare Part D formulary rules rather than commercial rules, which creates three distinct scenarios.

Scenario 1: Jardiance is on your plan's Part D formulary. You pay the applicable tier copay, which may range from $47 to over $100 per fill depending on whether you are in the deductible, initial coverage, or catastrophic coverage phase.

Scenario 2: Jardiance is not on your Part D formulary. You may request a formulary exception by having your physician submit a coverage determination request documenting that all formulary alternatives are contraindicated or clinically inferior for your specific situation.

Scenario 3: You are in the Medicare Part D coverage gap. As of 2024, the Inflation Reduction Act capped out-of-pocket drug costs for Medicare Part D enrollees at $3,300 for 2024 and $2,000 for 2025. The Centers for Medicare and Medicaid Services confirmed that the $2,000 out-of-pocket cap under the IRA takes effect January 1, 2025 [5]. For Medicare patients on costly branded drugs like Jardiance, this cap meaningfully reduces annual exposure.

Note that the Jardiance manufacturer savings card (described below) cannot be used for Medicare Part D patients. Medicare beneficiaries should ask their pharmacist about the Extra Help (Low Income Subsidy) program if cost remains prohibitive.

What to Do If BCBS Alabama Denies Coverage

Denials happen. They are not final. The federal No Surprises Act and existing state insurance regulations require BCBS Alabama to provide a written explanation for every denial, and you have the right to appeal through at least two internal levels before pursuing an external independent review.

The appeals process has four practical steps.

Step 1: Read the denial letter carefully. The specific reason (step therapy not completed, PA criteria not met, non-formulary status) determines your strongest counter-argument. A "not medically necessary" denial requires different documentation than a "formulary exclusion" denial.

Step 2: Ask your physician to write a letter of medical necessity. The letter should cite the relevant guideline (ADA 2024 Standards of Care, ACC/AHA heart failure guidelines, KDIGO 2022 CKD guidelines) and reference the specific clinical outcome data supporting Jardiance for your diagnosis. The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (Class I, Level A recommendation) states that SGLT2 inhibitors are recommended to reduce hospitalization and mortality in patients with heart failure with reduced ejection fraction [6].

Step 3: Submit your internal appeal within the deadline. BCBS Alabama commercial plans generally allow 180 days from the denial date to file a first-level internal appeal. Medicare Advantage plans allow 60 days. Missing this window forfeits your appeal rights.

Step 4: Request an external independent medical review if both internal levels fail. The Alabama Department of Insurance oversees this process for state-regulated plans. An independent review organization (IRO) then makes a binding determination within 45 days.

Nationally, roughly 40 to 60% of insurance denials that are formally appealed are overturned, according to data compiled from state insurance department annual reports. The strongest predictor of appeal success is specific guideline language attached to documented clinical need, not just a general physician request.

Cost-Reduction Strategies If You Are Paying Out of Pocket

Even with insurance, Jardiance can be expensive before your deductible is met. Several programs reduce that burden.

Jardiance Savings Card (Lilly/Boehringer Ingelheim). Commercially insured patients who are not enrolled in any federal healthcare program (Medicare, Medicaid, TRICARE) may pay as little as $10 per month through the manufacturer's savings card. The program is available at jardiance.com and requires annual re-enrollment. There is no income requirement.

GoodRx and similar discount platforms. GoodRx coupons for empagliflozin 10 mg can reduce the cash price at Alabama pharmacies to roughly $430, $490 depending on the dispensing pharmacy, a meaningful reduction from the $573, $620 retail price. GoodRx cannot be combined with insurance; you choose one or the other at the point of sale.

90-day supply. Many BCBS Alabama plans offer a lower effective per-dose cost for 90-day mail-order fills versus 30-day retail fills. A Tier 3 drug with a $75 copay per 30-day fill may carry only a $150, $175 copay for a 90-day mail-order supply.

Patient Assistance Programs. Boehringer Ingelheim's cares program provides free Jardiance to uninsured or underinsured patients who meet income criteria (generally at or below 400% of the federal poverty level). The application is available through needymeds.org or directly via Boehringer Ingelheim's patient assistance line.

The Clinical Evidence Supporting Jardiance Coverage

Insurance coverage decisions are not made in a clinical vacuum. The three major outcome trials for empagliflozin provide the evidentiary foundation that payers, physicians, and patients can reference during appeals and PA submissions.

EMPA-REG OUTCOME (type 2 diabetes with cardiovascular disease, N=7,020): Empagliflozin reduced the primary MACE composite by 14% versus placebo and reduced cardiovascular mortality by 38% [1]. This trial was the key study supporting the FDA's 2016 cardiovascular risk reduction labeling update.

EMPEROR-Reduced (heart failure with reduced ejection fraction, N=3,730): Empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for heart failure by 25% versus placebo (HR 0.75; 95% CI 0.65, 0.86; P<0.001). The full EMPEROR-Reduced results are published in the New England Journal of Medicine [7].

EMPA-KIDNEY (chronic kidney disease, N=6,609): Empagliflozin 10 mg reduced the composite of kidney disease progression or cardiovascular death by 28% versus placebo (HR 0.72; 95% CI 0.64, 0.82; P<0.001). The EMPA-KIDNEY trial results are published at NEJM.org [8].

These three datasets mean that when a patient with type 2 diabetes, heart failure, or CKD presents a PA request, the physician can attach data from multi-thousand-patient randomized controlled trials demonstrating mortality and hospitalization reduction. That evidence base makes "not medically necessary" a very difficult position for an insurer to sustain on appeal.

Frequently Asked Questions